A First-in-Human Study To Assess the Safety and Pharmacokinetics of Monoclonal Antibodies against Human Cytomegalovirus in Healthy Volunteers

Documenti analoghi

• Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation
  di: Maertens, Johan, et al.
  Pubblicazione: (2020)
• In Vitro Characterization of Human Cytomegalovirus-Targeting Therapeutic Monoclonal Antibodies LJP538 and LJP539
  di: Patel, Hetalkumar D., et al.
  Pubblicazione: (2016)
• A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Imidazolopiperazine KAF156 To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers
  di: Leong, F. Joel, et al.
  Pubblicazione: (2014)
• A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel spiroindolone KAE609, to assess the safety, tolerability and pharmacokinetics in healthy adult volunteers
  di: Leong, Joel, et al.
  Pubblicazione: (2014)
• Rhesus Cytomegalovirus Is Similar to Human Cytomegalovirus in Susceptibility to Βenzimidazole Nucleosides
  di: North, Thomas W., et al.
  Pubblicazione: (2004)